Citigroup
KLRA

Citigroup’s Kailera Therapeutics KLRA Stock Holding History

Citigroup’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Buy
+21,547
New +$474K ﹤0.01% 3929

Other funds holding KLRA

ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Citigroup's KLRA Position: Q2 2026 in Review

Citigroup opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 21,547 shares worth $475K. The stake represents ﹤0.01% of the portfolio and ranks #3929 among its holdings.

17 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Citigroup held 21,547 shares of Kailera Therapeutics worth $475K as of Q2 2026.
  • Kailera Therapeutics was a new Citigroup position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3929 holding.
  • 17 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.